VEGFA and metastatic colorectal cancer: Several targeted angiogenesis inhibitors, approved by the US Food and Drug Administration (FDA), have been developed, such as Bevacizumab (a monoclonal antibody that targets vascular endothelial growth factor (VEGF), which has proven to be effective for the treatment of solid cancers such as metastatic colorectal cancer [11].